TheraRadar
Clinical-Stage Companies / Sichuan Baili Pharmaceutical

Sichuan Baili Pharmaceutical

Pre-Approval PRO BETA
106
Total Trials
24
Phase 3
47
Phase 2
95
Recruiting
1022
Score

Pipeline by Phase

Phase 3
24
Phase 2
47
Phase 1
52

Therapeutic Focus

Solid Tumor Non-small Cell Lung Cancer Breast Cancer Head and Neck Squamous Cell Carcinoma HER2-positive Breast Cancer

Clinical Trials (106)

NCT06830889 Phase 3 RECRUITING

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Started: 6/3/2025

NCT06957886 Phase 3 RECRUITING

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Started: 5/15/2025

NCT07152405 Phase 3 RECRUITING

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Started: 9/24/2025

NCT07178795 Phase 3 RECRUITING

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Started: 9/29/2025

NCT06838273 Phase 3 RECRUITING

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Started: 2/24/2025

NCT06857175 Phase 3 RECRUITING

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Started: 3/25/2025

NCT06994195 Phase 3 RECRUITING

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Started: 8/4/2025

NCT06343948 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Started: 4/24/2024

NCT06382129 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)

Started: 5/17/2024

NCT06304974 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Started: 3/19/2024

NCT06382116 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

Started: 5/22/2024

NCT06500026 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Started: 8/7/2024

NCT06118333 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Started: 12/4/2023

NCT07502300 Phase 3 NOT YET RECRUITING

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Started: 4/1/2026

NCT07518173 Phase 3 NOT YET RECRUITING

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Started: 4/1/2026

NCT07518147 Phase 3 NOT YET RECRUITING

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Started: 4/1/2026

NCT06382142 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Started: 6/21/2024

NCT06316531 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Started: 5/8/2024

NCT05943795 Phase 3 ACTIVE NOT RECRUITING

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Started: 7/14/2023

NCT07545460 Phase 3 NOT YET RECRUITING

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Started: 4/1/2026

NCT07264816 Phase 2 RECRUITING

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Started: 2/3/2026

NCT06668961 Phase 2 RECRUITING

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Started: 11/7/2024

NCT06475300 Phase 2 RECRUITING

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Started: 6/25/2024

NCT07054567 Phase 2 RECRUITING

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Started: 8/21/2025

NCT06962787 Phase 2 RECRUITING

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Started: 7/28/2025

NCT06891833 Phase 2 RECRUITING

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Started: 6/5/2025

NCT06008054 Phase 2 RECRUITING

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Started: 11/16/2023

NCT05965856 Phase 2 RECRUITING

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Started: 12/11/2023

NCT06006169 Phase 2 RECRUITING

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Started: 10/20/2023

NCT05924841 Phase 2 RECRUITING

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Started: 11/10/2023

NCT05785039 Phase 2 RECRUITING

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

Started: 4/20/2023

NCT05990803 Phase 2 RECRUITING

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Started: 11/6/2023

NCT05956587 Phase 2 RECRUITING

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Started: 1/29/2024

NCT06042894 Phase 2 RECRUITING

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Started: 12/12/2023

NCT06986785 Phase 2 RECRUITING

A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Started: 6/24/2025

NCT06423885 Phase 2 RECRUITING

A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Started: 12/24/2024

NCT06445400 Phase 2 RECRUITING

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Started: 6/19/2024

NCT06978114 Phase 2 RECRUITING

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Started: 6/10/2025

NCT06471205 Phase 2 RECRUITING

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Started: 8/2/2024

NCT06598787 Phase 2 RECRUITING

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Started: 10/17/2024

NCT06437522 Phase 2 RECRUITING

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Started: 6/7/2024

NCT06498986 Phase 2 RECRUITING

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Started: 7/31/2024

NCT06437509 Phase 2 RECRUITING

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Started: 6/13/2024

NCT06405425 Phase 2 RECRUITING

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Started: 5/29/2024

NCT06787664 Phase 2 ACTIVE NOT RECRUITING

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma

Started: 1/16/2025

NCT07255872 Phase 2 NOT YET RECRUITING

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Started: 3/1/2026

NCT05054439 Phase 2 ACTIVE NOT RECRUITING

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Started: 12/22/2021

NCT05020769 Phase 2 ACTIVE NOT RECRUITING

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Started: 1/6/2022

NCT05044897 Phase 2 ACTIVE NOT RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Started: 10/20/2021

NCT05020457 Phase 2 ACTIVE NOT RECRUITING

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Started: 12/7/2021

NCT05022654 Phase 2 ACTIVE NOT RECRUITING

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Started: 12/13/2021

NCT05880706 Phase 2 ACTIVE NOT RECRUITING

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Started: 7/19/2023

NCT05039944 Phase 2 TERMINATED

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Started: 11/30/2021

NCT07554456 Phase 2 NOT YET RECRUITING

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Started: 4/1/2026

NCT06718621 Phase 1 RECRUITING

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Started: 2/12/2025

NCT06031584 Phase 1 RECRUITING

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Started: 1/19/2024

NCT07279428 Phase 1 RECRUITING

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Started: 1/12/2026

NCT06503783 Phase 1 RECRUITING

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Started: 8/24/2024

NCT06718634 Phase 1 RECRUITING

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Started: 1/2/2025

NCT06612840 Phase 1 RECRUITING

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors

Started: 10/16/2024

NCT06609187 Phase 1 RECRUITING

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Started: 10/30/2024

NCT07232407 Phase 1 RECRUITING

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Started: 11/14/2025

NCT07274852 Phase 1 RECRUITING

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Started: 12/10/2025

NCT07232524 Phase 1 RECRUITING

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Started: 12/10/2025

NCT07232420 Phase 1 RECRUITING

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Started: 11/11/2025

NCT06066203 Phase 1 RECRUITING

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Started: 11/1/2023

NCT04794972 Phase 1 RECRUITING

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Started: 4/14/2021

NCT05623982 Phase 1 RECRUITING

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Started: 9/26/2022

NCT05461768 Phase 1 RECRUITING

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Started: 8/9/2022

NCT05262491 Phase 1 RECRUITING

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Started: 2/14/2022

NCT05631964 Phase 1 RECRUITING

Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

Started: 1/5/2023

NCT05803018 Phase 1 RECRUITING

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Started: 6/25/2023

NCT05194982 Phase 1 RECRUITING

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Started: 11/29/2021

NCT06131450 Phase 1 RECRUITING

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Started: 2/29/2024

NCT05949606 Phase 1 RECRUITING

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Started: 10/30/2023

NCT05470348 Phase 1 RECRUITING

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Started: 8/11/2022

NCT05924750 Phase 1 RECRUITING

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Started: 8/2/2023

NCT05668858 Phase 1 RECRUITING

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Started: 2/10/2023

NCT06500052 Phase 1 RECRUITING

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Started: 7/24/2024

NCT06469008 Phase 1 RECRUITING

A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Started: 6/27/2024

NCT06505824 Phase 1 RECRUITING

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Started: 8/2/2024

NCT06475131 Phase 1 RECRUITING

A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Started: 7/18/2024

NCT06493864 Phase 1 RECRUITING

A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Started: 8/26/2024

NCT07056556 Phase 1 RECRUITING

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Started: 7/30/2025

NCT06114511 Phase 1 RECRUITING

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Started: 4/24/2024

NCT06857214 Phase 1 RECRUITING

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

Started: 6/4/2025

NCT06349811 Phase 1 RECRUITING

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Started: 4/19/2024

NCT06954077 Phase 1 RECRUITING

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Started: 5/15/2025

NCT06857227 Phase 1 RECRUITING

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Started: 3/17/2025

NCT07255898 Phase 1 NOT YET RECRUITING

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Started: 12/1/2025

NCT05949619 Phase 1 ACTIVE NOT RECRUITING

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Started: 9/4/2023

NCT05192486 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Started: 8/10/2022

NCT05944978 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Started: 8/16/2023

NCT04603287 Phase 1 ACTIVE NOT RECRUITING

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Started: 4/17/2020

NCT05627856 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Started: 2/21/2023

NCT04606433 Phase 1 ACTIVE NOT RECRUITING

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Started: 11/4/2020

NCT05485753 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Started: 2/10/2023

NCT05160545 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Started: 11/26/2021

NCT05104775 Phase 1 ACTIVE NOT RECRUITING

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Started: 2/9/2022

NCT05393427 Phase 1 ACTIVE NOT RECRUITING

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Started: 2/15/2022

NCT05385692 Phase 1 ACTIVE NOT RECRUITING

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Started: 6/1/2022

NCT04606472 Phase 1 ACTIVE NOT RECRUITING

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Started: 11/10/2020

NCT05339685 Phase 1 ACTIVE NOT RECRUITING

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

Started: 5/20/2022

NCT06755242 Phase 1 NOT YET RECRUITING

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Started: 1/1/2025

NCT05039931 Phase 1 WITHDRAWN

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Started: 9/15/2021

NCT04851444 Phase 1 COMPLETED

A Study of SI-F019 in Healthy Participants

Started: 3/30/2021

Drug Candidates

BL-B01D1 Eribulin Vinorelbine Gemcitabine Capecitabine Docetaxel Irinotecan paclitaxel docetaxel Pemetrexed+Cisplatin or Carboplatin
Activity Status: Active
Last Trial Started: 4/1/2026
Last Trial Ended: 6/6/2022
Trials (12 months): 26
Completed Trials: 1
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.